CGEN-15001 / Compugen, Bayer - LARVOL DELTA

Compugen's CEO discusses Q2 2012 results - Earnings call transcript (SeekingAlpha) - CGEN-15001 could be safer therapy with reduced risk of infection vs. significant risk posed by approved biologics for autoimmune diseases; Anticipated presentation at the European Congress of Immunology in Sep 2012

Preclinical • Immunology • Inflammatory Bowel Disease • Multiple Sclerosis • Rheumatoid Arthritis

Compugen's CGEN-15001 pre-clinical data presented at International Conference on Immune Tolerance (Compugen) - Compugen announced that CGEN-15001 was the subject of a presentation at the 2nd International Conference on Immune Tolerance, Amsterdam; CGEN-15001 appears to exert its beneficial therapeutic effect by modulating immune system & preventing infiltration of reactive immune T cells into central nervous system with similar beneficial effects were observed in two MS models, an EAE model actively induced by immunization with a myelin antigen & an adoptive transfer EAE model created by injection of immune cells specifically reactive to myelin

Data presentation • Preclinical-animal • Multiple Sclerosis

Compugen (CGEN) reprts updates to collaborative activities with Bayer in immuno-oncology (Streetinsider.com) - "...a recently completed joint assessment by Compugen and Bayer of potential drug candidates against the CGEN-15022 target program has suggested that its potential to serve as a key immune checkpoint for the treatment of cancer immunotherapy may be limited and does not justify further investment. Therefore, it has been determined that the current collaboration will focus solely on CGEN-15001T and all rights to CGEN-15022 will be returned to Compugen."

Licensing / partnership • Oncology